FDA reviewers told the advisory committee that BPC‑157 nominations lacked consistent chemical identification, complete certificates of analysis and robust human safety/effectiveness data; public commenters and many clinicians said regulated compounding access would reduce gray‑market harms and urged listing with safeguards.